RxDoctor Payments Data

Stephen Wright, MD

Family Medicine · Lapel, INNPI 1235143439

Payments from drug & device makers

$12,912in general payments, 2019–2025

Across 706 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Bayer$994
  • GSK$842
  • Pfizer$696
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,73199%
  • Education$1811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,912 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$213,978
Medicare patients
247
Services billed
23,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$80,201
XifaxanRifaximin13$39,493
JardianceEmpagliflozin28$35,177
OzempicSemaglutide12$28,383
EntrestoSacubitril/Valsartan28$25,184
XareltoRivaroxaban25$21,216
JanuviaSitagliptin Phosphate13$19,947
MyrbetriqMirabegron14$17,925
Mirabegron ErMirabegron13$13,722
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$8,440
Pregabalin15$6,362
Tamsulosin Hcl230$5,297
Atorvastatin Calcium322$4,789
PaxlovidNirmatrelvir/Ritonavir16$4,061
Omeprazole234$3,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$696$84,26271 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$261$39,49313 claims
Boehringer IngelheimJardiance$517$35,17728 claims
Novo NordiskOzempic$1,517$28,38312 claims
NovartisEntresto$260$25,18428 claims
Johnson & JohnsonXarelto$58$21,21625 claims
MerckJanuvia$106$19,94713 claims
Astellas Pharma US IncMyrbetriq$513$17,92514 claims
AbbVieSynthroid$1,579$1,24712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lapel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →